@Thompson_Chem
Joined November 2021
  • Tweets132
  • Following109
  • Followers98
11Media
I am happy to share a another manuscript by @BangyanXu, a fun collaboration with Simon and @Thompson_Chem. We report some new sulfoxonium ylide activity-based probes for cysteine cathepsins. Check it out! pubs.acs.org/doi/10.1021/acs…

Expanding the Library of Covalent Cysteine Cathepsin Probes Featuring Sulfoxonium Ylide Electroph...

Abstract. Covalent activity-based probes are invaluable tools to monitor protease activity in vitro and in vivo. We recently discovered that dimethyl sulfo

pubs.acs.org
6
20
1,349
PI3Kα degraders with α/β selectivity tunable based on linker composition. Structural rationale proposed. pubs.rsc.org/en/content/arti…

A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα†

Class I phosphoinositide 3-kinases (PI3Ks) control cellular growth, but are also essential in insulin signaling and glucose homeostasis. Pan-PI3K inhibitor

pubs.rsc.org
4
29
4,793
Test cricket Aus/WI; Eng /India - tennis - Socceroos. It’s all happening!
3
158
Philip Thompson retweeted
Guillaume Laconde@Glaconde345 Jan 2024
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance @NatureComms nature.com/articles/s41467-0…

DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and...

Nature Communications - Targeted protein degradation (TPD) is a key modality for drug discovery. Here the authors present the discovery and analysis of reversible DCAF1-PROTACs, which show efficacy...

nature.com
1
9
46
5,685
We're thrilled to announce our line up of confirmed speakers for our Symposium in May 2024! We invite you to apply via the link below. We hope you are as excited as we are for 3 days of science and Scottish fun! Apply-> buff.ly/40nLF45
6
25
8
101
42,912
Warpaint. Superb - so glad to see them live.
3
153
Philip Thompson retweeted
S P A R K S@sparksofficial26 Oct 2023
What an incredible return to Australia! Thank you, Melbourne!! 🇦🇺✨ #SparksTour2023
29
65
11
710
39,881
Philip Thompson retweeted
Nick Ede@Melroseavenick4 Oct 2023
Just a reminder of what @TeamRadioPharm could be worth.... Lilly to surf radiopharmaceutical wave with $1.4B acquisition of Point Biopharma fiercebiotech.com/biotech/li…

Lilly to surf radiopharmaceutical wave with $1.4B acquisition of Point Biopharma

Eli Lilly is snapping up Point Biopharma Global for $1.4 billion, marking an official entrance into the radiopharmaceutical cancer therapeutic space.  | Eli Lilly is snapping up Point Biopharma...

fiercebiotech.com
1
2
4
750
Philip Thompson retweeted
baolong pan@baolong_pan1 Oct 2023
Thrilled to share our latest work in antifungal drug discovery, it's now out in @ACSBioMed! Thanks to everyone involved for a fruitful collaboration. @TravenLab @HCWeerasinghe @MikeJayMcD @Thompson_Chem pubs.acs.org/doi/10.1021/acs…

Leveraging the MMV Pathogen Box to Engineer an Antifungal Compound with Improved Efficacy and...

Abstract. Fungal infections pose a significant and increasing threat to human health, but the current arsenal of antifungal drugs is inadequate. We screene

pubs.acs.org
1
3
2
381
Philip Thompson retweeted
Liam Hales@LiamHalesMRCPPU1 Oct 2023
Replying to @baolong_pan @ACSBioMed @TravenLab @MikeJayMcD @Thompson_Chem
Congrats!!!
1
1
117
Check out our August 2023 CeTPD journal club issue, covering some of the latest work in TPD. buff.ly/45S7GtO There are lots of great reads contained within! Edited by: @ManjulaNagala, @MarcoSe45278655 & @rcasement255 #openaccess #journalclub @UoDLifeSciences
The front page of the August edition of CeTPD journal club, showing a chemist at their fume hood

ALT The front page of the August edition of CeTPD journal club, showing a chemist at their fume hood

8
2
14
6,903
Philip Thompson retweeted
drug hunter
@drughunter_com12 Sep 2023
This year, the team at Novartis published a tour de force campaign to rationally identify novel DCAF1 ligands and develop non-covalent DCAF1-based PROTACs that differentiate from existing CRBN-based PROTACs. Full article: drughunters.com/48bExv9
1
14
65
7,331
Solid‐Phase Synthesis of PROTACs and SNIPERs on Backbone Amide Linked (BAL) Resin - Hales - Chemistry – A European Journal - Wiley Online Library chemistry-europe.onlinelibra…

Solid‐Phase Synthesis of PROTACs and SNIPERs on Backbone Amide Linked (BAL) Resin

Solid-phase approaches could offer many advantages over conventional PROTAC synthesis if the same chemistries and topographic diversity can be incorporated. We have examined solid-phase synthesis of...

chemistry-europe.onlinelibrary.wiley.com
11
336
Philip Thompson retweeted
Ingo Hartung@HartungIngo6 Sep 2023
Cool double whopper lecture by Martin Schröder & Anna Vulpetti @NovartisScience about #DCAF1 ligand discovery & application to #PROTAC design. Still more research needed to understand why cancer cells are more dependent on DCAF1 than on #CRBN. #EFMCASMC23 @EuroMedChem
9
32
3,603
Philip Thompson retweeted
Liam Hales@LiamHalesMRCPPU5 Sep 2023
Had a lot of fun sharing the work from my recent paper with those at #EFMCASMC23 It's been a great conference so far with plenty more chemistry to come! Have a read here: …mistry-europe.onlinelibrary.……
3
32
4,935
Team led by Profs @Thompson_Chem, @JakeShortt3 & Ricky Johnstone have designed a single drug that delivers a lethal ‘one-two’ punch to several types of blood cancer in preclinical studies. @SCSMonash @PeterMacCC @PNASNews monash.edu/pharm/about/news/…
6
1
10
2,103
Peter Mac's @JohnstoneRicky and @MonashUni researchers have designed a single drug that delivers a lethal ‘one-two’ punch to several types of #bloodcancer in preclinical studies and could lead to improved treatments. Read the full story: petermac.org/about-us/news-a…
2
1
20
2,478
Absolutely rapt to have this paper published in PNAS. Great to collaborate with @JakeShortt3 and Phil Thompson from @MonashUni on this project with more exciting stuff to come! Thanks to all @PeterMacRes @PeterMacCC for continued support.
Jake Shortt@JakeShortt331 Aug 2023
Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma | PNAS pnas.org/doi/abs/10.1073/pna… Proud of our collaborative effort. Great working @SCSMonash with @JohnstoneRicky and @MIPS_Australia. Thanks to @NFMRI for the support.
2
5
29
3,492
Philip Thompson retweeted
Jake Shortt@JakeShortt331 Aug 2023
Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma | PNAS pnas.org/doi/abs/10.1073/pna… Proud of our collaborative effort. Great working @SCSMonash with @JohnstoneRicky and @MIPS_Australia. Thanks to @NFMRI for the support.
1
3
4
25
6,967
Reasonable look at what’s going on with degraders in the antiviral space. Very early days. sciencedirect.com/science/ar…
6
18
2,175
Load more